Pharvaris announced two oral and six poster presentations at ACAAI 2025, highlighting innovations in bradykinin-mediated disease treatments.
Quiver AI Summary
Pharvaris, a biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases, announced the acceptance of two abstracts for oral presentation and six for poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting in Orlando, Florida, from November 6-10, 2025. Key topics include the clinical validation of a kinin biomarker assay and the long-term safety and efficacy of their drug, deucrictibant, for prophylaxis in hereditary angioedema. The presentations will showcase various studies on the treatment and management of hereditary angioedema, emphasizing improvements in disease control and patient quality of life. The company aims to provide effective oral therapies with the safety profile of injectables, with ongoing pivotal Phase 3 studies for both prophylactic and on-demand treatment of HAE attacks.
Potential Positives
- Pharvaris will present two abstracts as oral presentations and six as poster presentations at the prestigious American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting, which enhances the company's visibility within the scientific and medical community.
- The presentations will include significant clinical data on oral deucrictibant, potentially showcasing its long-term safety and efficacy for hereditary angioedema, thus reinforcing the company's commitment to addressing unmet medical needs.
- Positive data from both Phase 2 studies and ongoing pivotal Phase 3 studies suggest strong prospects for the company's products, potentially leading to advancements in treatment options for patients suffering from bradykinin-mediated diseases.
- The company aims to offer a novel oral therapy with injectable-like efficacy and placebo-like tolerability, aligning with the evolving needs of patients and the healthcare market for more convenient treatment options.
Potential Negatives
- None
FAQ
What is Pharvaris presenting at the ACAAI 2025 Annual Scientific Meeting?
Pharvaris will present two oral abstracts and six poster abstracts related to bradykinin-mediated diseases.
When is the ACAAI 2025 Annual Scientific Meeting?
The conference will be held from November 6-10, 2025, in Orlando, Florida.
Who are the presenters for the oral presentations?
The oral presentations will feature Dr. Evangelia Pardali and Dr. Marc A. Riedl.
What is the focus of Pharvaris' research?
Pharvaris is focused on developing oral bradykinin B2 receptor antagonists for treating hereditary angioedema and acquired angioedema.
Where can I find the presentation materials?
The presentation materials will be available on the Investors section of the Pharvaris website during the respective presentations.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PHVS Hedge Fund Activity
We have seen 30 institutional investors add shares of $PHVS stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VR ADVISER, LLC removed 1,065,100 shares (-34.2%) from their portfolio in Q2 2025, for an estimated $18,745,760
- PARADIGM BIOCAPITAL ADVISORS LP added 1,062,911 shares (+inf%) to their portfolio in Q2 2025, for an estimated $18,707,233
- DEERFIELD MANAGEMENT COMPANY, L.P. added 827,121 shares (+69.5%) to their portfolio in Q2 2025, for an estimated $14,557,329
- OCTAGON CAPITAL ADVISORS LP added 364,595 shares (+118.4%) to their portfolio in Q2 2025, for an estimated $6,416,872
- PRICE T ROWE ASSOCIATES INC /MD/ added 181,228 shares (+30.9%) to their portfolio in Q2 2025, for an estimated $3,189,612
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 81,684 shares (-10.0%) from their portfolio in Q2 2025, for an estimated $1,437,638
- SPHERA FUNDS MANAGEMENT LTD. removed 73,925 shares (-19.3%) from their portfolio in Q2 2025, for an estimated $1,301,080
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PHVS Analyst Ratings
Wall Street analysts have issued reports on $PHVS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/15/2025
- JMP Securities issued a "Market Outperform" rating on 08/13/2025
- Wedbush issued a "Outperform" rating on 06/05/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/14/2025
To track analyst ratings and price targets for $PHVS, check out Quiver Quantitative's $PHVS forecast page.
$PHVS Price Targets
Multiple analysts have issued price targets for $PHVS recently. We have seen 6 analysts offer price targets for $PHVS in the last 6 months, with a median target of $27.5.
Here are some recent targets:
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $60.0 on 10/15/2025
- Tazeen Ahmad from B of A Securities set a target price of $27.0 on 10/09/2025
- Jonathan Wolleben from JMP Securities set a target price of $52.0 on 08/13/2025
- Laura Chico from Wedbush set a target price of $27.0 on 06/05/2025
- Timur Ivannikov from Cantor Fitzgerald set a target price of $25.0 on 05/14/2025
Full Release
ZUG, Switzerland, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of two abstracts for oral presentation and six for poster presentation at the American College of Allergy, Asthma, and Immunology (ACAAI) 2025 Annual Scientific Meeting to be held from November 6-10, in Orlando, Florida.
Details of the presentations are as follows:
ACAAI 2025
, Orlando, Florida, November 6-10, 2025.
Oral Presentations
-
Title:
Clinical Validation of a Kinin Biomarker Assay to Characterize Bradykinin-Mediated Angioedema
Presenter: Evangelia Pardali, Ph.D.
Format: Oral Presentation
Date, time: Saturday, November 8, 4:43 p.m. ET
-
Title:
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: CHAPTER-1 Open-Label Extension
Presenter: Marc A. Riedl, M.D., M.S.
Format: Oral Presentation
Date, time: Saturday, November 8, 4:53 p.m. ET
Poster Presentations
-
Title:
Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Disease Control and Health-Related Quality of Life in Hereditary Angioedema: CHAPTER-1
Presenter: Michael E. Manning, M.D.
Format: Poster Presentation
Date, time: Friday, November 7, 2:35 p.m. ET
-
Title:
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: RAPIDe-2 Results
Presenter: John Anderson, M.D.
Format: Poster Presentation
Date, time: Friday, November 7, 2:35 p.m. ET
-
Title:
Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis
Presenter: Mark D. Scarupa, M.D.
Format: Poster Presentation
Date, time: Friday, November 7, 4:35 p.m. ET
-
Title:
Durability of Response to Single Dose Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks
Presenter: Joshua S. Jacobs, M.D.
Format: Poster Presentation
Date, time: Friday, November 7, 5:05 p.m. ET
-
Title:
Outcomes of Deucrictibant-Treated Upper Airway and Laryngeal Hereditary Angioedema Attacks: RAPIDe-2 Part A Results
Presenter: John Anderson, M.D.
Format: Poster Presentation
Date, time: Friday, November 7, 5:20 p.m. ET
-
Title:
Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
Presenter: Zhi-Yi Zhang, Ph.D.
Format: Poster Presentation
Date, time: Friday, November 7, 5:35 p.m. ET
The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: https://ir.pharvaris.com/news-events/events-presentations .
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy™ and placebo-like tolerability with the convenience of oral therapies to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit
https://pharvaris.com/
.
